Loading clinical trials...
Loading clinical trials...
A Phase I/II Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/13 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Matrix-M1™
Conditions
Interventions
Monovalent Avian Influenza VLP (H7N9)
Matrix-M1™ adjuvant
+1 more
Locations
5
United States
Diablo Clinical Research
Walnut Creek, California, United States
Miami Research Associates
Miami, Florida, United States
Advanced Clinical Research
Meridian, Idaho, United States
Regional Clinical Research, Inc.
Endwell, New York, United States
Coastal Carolina Research
Mt. Pleasant, South Carolina, United States
Start Date
March 1, 2014
Primary Completion Date
July 1, 2015
Completion Date
July 1, 2015
Last Updated
September 23, 2016
Lead Sponsor
Novavax
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions